

# Cynata Therapeutics (CYP)

Rating: Buy | Risk: High | Price Target: \$2.50

## Extension of Option Delivers Buying Opportunity

### Key Information

Current Price (\$ps)	1.18
12m Target Price (\$ps)	2.50
52 Week Range (\$ps)	0.97 - 1.79
Target Price Upside (%)	111.9%
TSR (%)	111.9%
Reporting Currency	AUD
Market Cap (\$m)	120.2
Sector	Health Care
ASX 200 Weight (%)	0%

### Fundamentals

YE 30 Jun (AUD)	FY18A	FY19E	FY20E	FY21E
Sales (\$m)	0.0	0.0	15.6	42.6
NPAT (\$m)	(4.6)	(7.3)	4.0	23.0
EPS (cps)	(5.1)	(7.7)	4.2	24.2
EPS Growth (%)	25.3%	(52.0%)	154.0%	481.4%
DPS (cps) (AUD)	0.0	0.0	0.0	0.0
Franking (%)	0%	0%	0%	0%

### Ratios

YE 30 Jun	FY18A	FY19E	FY20E	FY21E
P/E (x)	(26.9)	(15.3)	28.4	4.9
EV/EBITDA (x)	(27.4)	(14.9)	25.1	3.9
Div Yield (%)	0.0%	0.0%	0.0%	0.0%
Payout Ratio (%)	0.0%	0.0%	0.0%	0.0%

### Price Performance

YE 30 Jun	1 Mth	2 Mth	3 Mth	1 Yr
Relative (%)	(25.4%)	(18.7%)	(11.7%)	(23.5%)
Absolute (%)	(25.6%)	(14.8%)	(2.1%)	(18.3%)
Benchmark (%)	(0.2%)	3.9%	9.6%	5.2%



Price performance indexed to 100

Source:

### Major Shareholders

Fidelity	9.4%
FUJIFILM Corporation	8.0%
Washer, Stewart	2.7%
McDonald, Ross	2.5%
Slukvin, Igor	2.4%

### Event

Following the extension of Fujifilm’s option to license CYP-001 for GvHD, CYP’s share price is down 30%. We look at a number of factors concluding this is a buying opportunity. Our forecasts are revised down to reflect the delay. Our TP and rating remain unchanged. Buy.

### Highlights

- Fujifilm option extended by six months.** The term of Fujifilm’s option to licence CYP’s lead candidate CYP-001 for graft-versus-host disease (GvHD) has been extended to 5:00pm (Melbourne time) 19 Sept 2019. The option was due to expire on 19 March, however undisclosed “structural aspects” of the agreement prevented execution. CYP stated that Fujifilm did not raise any material issues in respect of the financial, clinical or technical aspects of CYP-001 and that it is not negotiating any changes to those terms and no changes have been agreed (for terms of the agreement see our note dated 18 March). Factors that suggest Fujifilm will exercise the option include:
  - Fujifilm’s USD900m acquisition of Biogen’s biologics facility.** On March 12, Fuji announced the acquisition of Biogen’s Danish biologics manufacturing site stating that the “significant investment demonstrates our commitment to grow the Bio CBMO business and become an industry leader”. Finalising this transaction may have taken precedence over addressing the undisclosed structural aspects of the CYP option deal, mentioned above.
  - Fujifilm has indicated intentions to accelerate the development of CYP’s MSCs.** The Fujifilm investor deck from January 2019 had three pages dedicated to CYP’s MSCs. The commentary emphasised Fujifilm’s intention to accelerate development of its own IPS programs while reducing risks, and
  - Fujifilm’s Advertisement in Nature magazine** During February 2019 Fujifilm ran a series of advertisements directly inside the front cover of the publication Nature and Science highlighting its progress in regenerative medicine and its ambitions in the future based on CYP’s Cymerus™ technology.
- GvHD advances are now matched by CYP’s Osteoarthritis program.** In December CYP announced that the NHMRC would fund via grant a phase 2 Osteoarthritis clinical trial in 448 patients. This will not only be one of the largest MSC trials ever undertaken, but targets a market opportunity est at USD11.6b by 2025 and CYP shareholders will not be diluted or lose any interest in the program.
- CYP’s other partnering opportunities also continue to progress.** CYP announced at its AGM that a number of other indications are moving towards licensing. Indications, timeframes and likely partners have not been disclosed, however CYP’s MSC’s have broad application in indications such as: Asthma, Crohn’s Disease, Critical Limb Ischemia and Coronary Artery Disease.
- Shaw forecasts.** Our forecasts are revised down to reflect the delay in likely payments from Fujifilm exercising its option. Our forecasts are also adjusted to recognise CYP’s current burn of \$0.6m pm and the commencement of the Osteoarthritis trial in 2H19.

### Recommendation

We believe if Fujifilm didn’t want to exercise its option it would have walked and continue to expect it will exercise the option which will be i) strong validation of CYP’s Cymerus platform, ii) see CYP-001 move into GvHD phase 2 trials in 2019, and iii) deliver substantial value to CYP (up fronts, milestones and royalties). Should Fujifilm not take up its option, negative sentiment will impact CYP’s share price however we believe it is trading at an undemanding capitalisation and that the progress on various indications has been substantive. CYP would then remain well-funded to support ongoing product development, including initiating three Phase 2 clinical trial programs in 2019 for the treatment of GvHD, Critical Limb and Osteoarthritis. Shaw and Partners forecasts are revised down. Our target price and BUY recommendation remain unchanged.

**Darren Vincent** | Senior Analyst

+61 2 9238 1269

[dvincent@shawandpartners.com.au](mailto:dvincent@shawandpartners.com.au)

## Cynata Therapeutics

### Health Care

### Pharmaceuticals, Biotechnology & Life Sciences



FactSet: CYP-AU / Bloomberg: CYP AU

Key Items	Data
Recommendation	BUY
Risk	HIGH
Price (\$ps)	1.18
Target Price (\$ps)	2.50
52 Week Range (\$ps)	0.97 - 1.79
Shares on Issue (m)	101.8
Market Cap (\$m)	120.2
Enterprise Value (\$m)	105.3
TSR (%)	111.9%

Valuation NPV	Data
Beta	1.50
Cost of Equity (%)	12.5%
Cost of Debt (net) (%)	7.5%
Risk Free Rate (%)	5.0%
Terminal Growth (%)	3.0%
WACC (%)	16.2%

### Company Description

Cynata Therapeutics Ltd. is a stem cell and regenerative medicine company, which develops a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison. The company IPO'd in November 2013 and is headquartered in Carlton, Australia.



### Financial Year End: 30 June

Investment Summary (AUD)	FY17A	FY18A	FY19E	FY20E	FY21E
EPS (Reported) (cps)	(6.8)	(5.1)	(7.7)	4.2	24.2
EPS (Underlying) (cps)	(6.8)	(5.1)	(7.7)	4.2	24.2
EPS (Underlying) Growth (%)		25.3%	(52.0%)	154.0%	481.4%
PE (Underlying) (x)	(9.0)	(26.9)	(15.3)	28.4	4.9
EV / EBIT (x)	(8.8)	(25.7)	(14.4)	26.9	4.0
EV / EBITDA (x)	(9.3)	(27.4)	(14.9)	25.1	3.9
DPS (cps) (AUD)	0.0	0.0	0.0	0.0	0.0
Dividend Yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Franking (%)	0%	0%	0%	0%	0%
Payout Ratio (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Free Cash Flow Yield (%)	(7.9%)	(3.1%)	(5.3%)	(0.9%)	13.3%
Profit and Loss (AUD) (m)	FY17A	FY18A	FY19E	FY20E	FY21E
Sales	0.0	0.0	0.0	15.6	42.6
Sales Growth (%)					172.2%
Other Operating Income	1.1	1.5	1.6	1.5	2.9
EBITDA	(4.8)	(4.3)	(7.0)	4.2	23.3
EBITDA Margin (%)	nm	nm	nm	27.1%	54.7%
Depreciation & Amortisation	(0.3)	(0.3)	(0.3)	(0.3)	(0.3)
EBIT	(5.1)	(4.6)	(7.3)	4.0	23.0
EBIT Margin (%)	nm	nm	nm	25.3%	54.1%
Net Interest	0.1	0.0	0.0	0.0	0.0
Pretax Profit	(4.9)	(4.6)	(7.3)	4.0	23.0
Tax	0.0	0.0	0.0	0.0	0.0
Tax Rate (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Minorities	0.0	0.0	0.0	0.0	0.0
NPAT Underlying	(4.9)	(4.6)	(7.3)	4.0	23.0
Significant Items	0.0	0.0	0.0	0.0	0.0
NPAT Reported	(4.9)	(4.6)	(7.3)	4.0	23.0
Cashflow (AUD) (m)	FY17A	FY18A	FY19E	FY20E	FY21E
EBIT	(5.1)	(4.6)	(7.3)	4.0	23.0
Tax Paid	0.0	0.0	0.0	0.0	0.0
Net Interest	0.1	0.2	0.1	0.0	0.0
Other	0.6	0.3	1.3	(4.9)	(8.1)
Operating Cashflow	(4.3)	(4.1)	(5.9)	(1.0)	14.9
Capex	0.0	0.0	0.0	0.0	0.0
Acquisitions and Investments	0.0	0.0	0.0	0.0	0.0
Disposal of Fixed Assets/Investments	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0
Investing Cashflow	0.0	0.0	0.0	0.0	0.0
Free Cashflow	(4.3)	(4.1)	(5.9)	(1.0)	14.9
Equity Raised / Bought Back	5.0	5.9	0.4	0.0	0.0
Dividends Paid	0.0	0.0	0.0	0.0	0.0
Change in Debt	0.0	0.0	0.0	0.0	0.0
Other	(0.5)	0.0	0.2	0.0	0.0
Financing Cashflow	4.5	5.9	0.6	0.0	0.0
Net Change in Cash	0.2	1.8	(5.3)	(1.0)	14.9
Balance Sheet (AUD) (m)	FY17A	FY18A	FY19E	FY20E	FY21E
Cash	10.3	12.2	6.9	5.9	20.8
Accounts Receivable	0.1	0.4	0.0	5.6	14.4
Inventory	0.0	0.0	0.0	0.0	0.0
Other Current Assets	0.0	0.0	1.8	1.8	1.8
PPE	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangibles	3.8	3.5	3.3	3.0	2.7
Investments	0.0	0.0	0.0	0.0	0.0
Other Non Current Assets	0.0	0.0	0.0	0.0	0.0
Total Assets	14.3	16.1	11.9	16.3	39.7
Accounts Payable	0.4	0.7	0.4	0.6	1.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0
Long Term Debt	0.0	0.0	0.0	0.0	0.0
Income Taxes Payable	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0
Total Liabilities	0.4	0.7	0.4	0.6	1.0
Ratios	FY17A	FY18A	FY19E	FY20E	FY21E
ROE (%)		(29.1%)	(52.4%)	31.2%	85.8%
Gearing (%)	(278.5%)	(383.7%)	(147.8%)	(60.4%)	(116.6%)
Net Debt / EBITDA (x)	2.2	2.8	1.0	(1.4)	(0.9)

## Contacts Page

### Equities

<b>Head of Equities</b>	Mike Ryan	+612 9238 1527	mryan@shawandpartners.com.au
-------------------------	-----------	----------------	------------------------------

### Chief Investment Officer

	Martin Crabb	+612 9238 1352	mcrabb@shawandpartners.com.au
--	--------------	----------------	-------------------------------

### Research

Banks, Insurance	Brett Le Mesurier	+612 9238 1256	blemesurier@shawandpartners.com.au
Retailers, Technology	Danny Younis	+612 9238 1292	dyounis@shawandpartners.com.au
Technology, Life Sciences, Industry Consolidators	Darren Vincent	+612 9238 1269	dvincent@shawandpartners.com.au
Consumer Discretionary, Info Technology	Jonathon Higgins	+613 9268 1182	jhiggins@shawandpartners.com.au
Metals & Mining	Peter O'Connor	+612 9238 1219	poconnor@shawandpartners.com.au
Real Estate	Peter Zuk	+612 9238 1211	pzuk@shawandpartners.com.au
Oil & Gas	Stuart Baker	+613 9268 1148	sbaker@shawandpartners.com.au

### Income Strategies

	Cameron Duncan	+612 9238 1544	cduncan@shawandpartners.com.au
	Steve Anagnos	+612 9238 1513	sanagnos@shawandpartners.com.au

### Institutional Equities

	David Erskine	+613 9268 1061	derskine@shawandpartners.com.au
	Edward Walker	+612 9238 1367	ewalker@shawandpartners.com.au
	James Diamond	+612 9238 1503	jdiamond@shawandpartners.com.au
	John Bowie Wilson	+612 9238 1253	jbowiewilson@shawandpartners.com.au
	Roger Gamble	+613 9268 1107	rgamble@shawandpartners.com.au
	Sam Kanaan	+612 9238 1275	skanaan@shawandpartners.com.au
	Scott Coventry	+612 9238 1363	scoventry@shawandpartners.com.au

### Corporate Finance

<b>Head of Corporate Finance</b>	Geoff Carrick	+612 9238 1339	gcarrick@shawandpartners.com.au
	Damian Rigney	+612 9238 1398	drigney@shawandpartners.com.au
	David Kells	+612 9238 1362	dkells@shawandpartners.com.au
	Edward Loneragan	+612 9238 1283	eloneragan@shawandpartners.com.au
	George BouAntoun	+612 9238 1597	gbouantoun@shawandpartners.com.au
	Grace Belsito	+612 9238 1226	gbelsito@shawandpartners.com.au
	Jeremy D'Sylva	+612 9238 1239	jdsylva@shawandpartners.com.au
	Jock Rayner	+612 9238 1268	jrayner@shawandpartners.com.au
	Nick Tregoning	+612 9238 1397	ntregoning@shawandpartners.com.au
	Robert Hallam	+612 9238 1594	rhallam@shawandpartners.com.au

Sydney   Head Office	Melbourne	Brisbane	Perth	Adelaide	Canberra
L15, 60 Castlereagh Street Sydney NSW 2000	L20, 90 Collins Street Melbourne VIC 3000	L28, 111 Eagle Street Brisbane QLD 4000	L14, 197 St Georges Terrace Perth WA 6000	L23, 91 King William Street Adelaide SA 5000	L7, 54 Marcus Clarke Street Canberra ACT 2600
Telephone: +61 2 9238 1238 Fax: +61 2 9232 1296 Toll Free: 1800 636 625	Telephone: +61 3 9268 1000 Fax: +61 3 9650 2277 Toll Free: 1800 150 009	Telephone: +61 7 3036 2500 Fax: +61 7 3036 2599 Toll Free: 1800 463 972	Telephone: +61 8 6188 7643 Fax: +61 8 6188 7607 Toll Free: 1800 636 625	Telephone: +61 8 7109 6000 Fax: +61 2 9232 1296 Toll Free: 1800 636 625	Telephone: +61 2 6113 5300 Fax: +61 2 6113 5399 Toll Free: 1800 636 625

## Rating Classification

<b>Buy</b>	Expected to outperform the overall market
<b>Hold</b>	Expected to perform in line with the overall market
<b>Sell</b>	Expected to underperform the overall market
<b>Not Rated</b>	Shaw has issued a factual note on the company but does not have a recommendation

## Risk Rating

<b>High</b>	Higher risk than the overall market – investors should be aware this stock may be speculative
<b>Medium</b>	Risk broadly in line with the overall market
<b>Low</b>	Lower risk than the overall market

**RISK STATEMENT:** Where a company is designated as ‘High’ risk, this means that the analyst has determined that the risk profile for this company is significantly higher than for the market as a whole, and so may not suit all investors. Clients should make an assessment as to whether this stock and its potential price volatility is compatible with their financial objectives. Clients should discuss this stock with their Shaw adviser before making any investment decision.

## Disclaimer

Shaw and Partners Limited ABN 24 003 221 583 (“Shaw”) is a Participant of ASX Limited, Chi-X Australia Pty Limited and holder of Australian Financial Services Licence number 236048.

**ANALYST CERTIFICATION:** The Research Analyst who prepared this report hereby certifies that the views expressed in this document accurately reflect the analyst's personal views about the Company and its financial products. The Research Analyst has not been, is not, and will not be receiving direct or indirect compensation for expressing the specific recommendations or views in this report. As at the date of this report the Research Analyst does not have an interest in the financial products of the Company.

**DISCLAIMER:** This report is published by Shaw to its clients by way of general, as opposed to personal, advice. This means it has been prepared for multiple distribution without consideration of your investment objectives, financial situation and needs (“personal circumstances”). Accordingly, the advice given is not a recommendation that a particular course of action is suitable for you and the advice is therefore not to be acted on as investment advice. You must assess whether or not the advice is appropriate for your personal circumstances before making any investment decisions. You can either make this assessment yourself, or if you require a personal recommendation, you can seek the assistance of your Shaw client adviser. This report is provided to you on the condition that it not be copied, either in whole or in part, distributed to or disclosed to any other person. If you are not the intended recipient, you should destroy the report and advise Shaw that you have done so. This report is published by Shaw in good faith based on the facts known to it at the time of its preparation and does not purport to contain all relevant information with respect to the financial products to which it relates. Although the report is based on information obtained from sources believed to be reliable, Shaw does not make any representation or warranty that it is accurate, complete or up to date and Shaw accepts no obligation to correct or update the information or opinions in it. If you rely on this report, you do so at your own risk. Any projections are estimates only and may not be realised in the future. Except to the extent that liability under any law cannot be excluded, Shaw disclaims liability for all loss or damage arising as a result of any opinion, advice, recommendation, representation or information expressly or impliedly published in or in relation to this report notwithstanding any error or omission including negligence. This publication has been prepared in accordance with Shaw’s Research Policy. A copy of the Policy can be found at [www.shawandpartners.com.au](http://www.shawandpartners.com.au).

**DISCLOSURE:** Shaw will charge commission in relation to client transactions in financial products and Shaw client advisers will receive a share of that commission. Shaw, its authorised representatives, its associates and their respective officers and employees may have earned previously, or may in the future earn fees and commission from dealing in the Company's financial products. Shaw acted for the company in a corporate capacity within the past 12 months for which it received a fee.

Sydney   Head Office	Melbourne	Brisbane	Perth	Adelaide	Canberra
L15, 60 Castlereagh Street Sydney NSW 2000	L20, 90 Collins Street Melbourne VIC 3000	L28, 111 Eagle Street Brisbane QLD 4000	L14, 197 St Georges Terrace Perth WA 6000	L23, 91 King William Street Adelaide SA 5000	L7, 54 Marcus Clarke Street Canberra ACT 2600
Telephone: +61 2 9238 1238	Telephone: +61 3 9268 1000	Telephone: +61 7 3036 2500	Telephone: +61 8 6188 7643	Telephone: +61 8 7109 6000	Telephone: +61 2 6113 5300
Fax: +61 2 9232 1296	Fax: +61 3 9650 2277	Fax: +61 7 3036 2599	Fax: +61 8 6188 7607	Fax: +61 2 9232 1296	Fax: +61 2 6113 5399
Toll Free: 1800 636 625	Toll Free: 1800 150 009	Toll Free: 1800 463 972	Toll Free: 1800 636 625	Toll Free: 1800 636 625	Toll Free: 1800 636 625